Skye ac­quires Bird Rock Bio, weeks af­ter No­vo Nordisk says it will buy a CB1 de­vel­op­er

Skye Bio­science ac­quired Bird Rock Bio to get its hands on an as­set tar­get­ing CB1 just two weeks af­ter No­vo Nordisk dipped its toes in­to the once-hot space to buy In­ver­sa­go Phar­ma, an­oth­er de­vel­op­er of CB1 ther­a­pies.

The San Diego biotech said Mon­day morn­ing it ac­quired Bird Rock’s out­stand­ing stock for to­tal con­sid­er­a­tion of about $20 mil­lion. Bird Rock, a Ver­sant Ven­tures- and 5AM-backed start­up, had said lit­tle in the three years since an­nounc­ing a Phase II IND ap­pli­ca­tion for its CB1 an­ti­body ni­macimab for var­i­ous re­nal dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER